Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)

Concurrent chemoradiotherapy (CHRT) remains the therapeutic standard for locally advanced inoperable non-small-cell lung cancer (NSCLC). The median overall survival (OS) with this approach is in the range of 20–30 months, with five-year survival of approximately 30%. These outcomes have recently bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Łazar-Poniatowska, Małgorzata, Bandura, Artur, Dziadziuszko, Rafał, Jassem, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Radiotherapy in Thoracic Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107727/
https://www.ncbi.nlm.nih.gov/pubmed/34012811
http://dx.doi.org/10.21037/tlcr-20-704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107727/
https://www.ncbi.nlm.nih.gov/pubmed/34012811
http://dx.doi.org/10.21037/tlcr-20-704

Ejemplares similares